Xcelience, an early drug development company, has expanded clinical trial supplies manufacturing and packaging capabilities to include four new pieces of manufacturing equipment and a new fully-automated packaging line.
To complement existing expertise in matrix tablet delivery systems, Xcelience added a MG Futura (capsule-filling machine for powder and pellets), LCI Multi-granulator MG-55 (extruder), QJ-230T marumerizer (spheronizer), and wurster insert (bottom spray) to the existing Glatt GPCG-3 fluid bed processor. These new pieces enable production, coating and encapsulation of MUDF delivery systems.
“The addition of the MG Futura improves production times, increases overall capacity, and expands upon our existing capabilities for powders, pellets and powder micro-dosing for inhalation systems,” says Theodore Koontz, Director of Operations.
In addition, Xcelience has added a fully-automated packaging line (including ink-jet coding) for primary bottling of tablets and capsules. The new packaging line enhances the speed at which batches are packaged, shortens timelines to clinical trials, and enhances our ability to package larger batches of drug product.
